Selected research
Industry Research
Insulin Drugs for Diabetes Industry Research Report 2026
Market perspective
The global Insulin Drugs for Diabetes market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Insulin Drugs for Diabetes is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Insulin Drugs for Diabetes is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Insulin Drugs for Diabetes is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Insulin Drugs for Diabetes include AstraZeneca, Bayer, Eli Lilly, HTBT, Merck, Novartis, Novo Nordisk, Sanofi and Tonghua Dongbao Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Insulin Drugs for Diabetes market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Insulin Drugs for Diabetes Market by Company
AstraZeneca
Bayer
Eli Lilly
HTBT
Merck
Novartis
Novo Nordisk
Sanofi
Tonghua Dongbao Pharmaceutical
Gan & Lee Pharmaceuticals
Kamp Pharmaceuticals
Johnson & Johnson
Wanbang Biopharmaceuticals
Takeda
Insulin Drugs for Diabetes Segment by Type
Ultra-long-acting Insulin
Short-acting Insulin
Rapid-acting Insulin
Long-acting Insulin
Intermediate-acting Insulin
Insulin Drugs for Diabetes Segment by Application
Hospital and Clinic
Retail Pharmacies
Other
Insulin Drugs for Diabetes Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Insulin Drugs for Diabetes market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Insulin Drugs for Diabetes and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Insulin Drugs for Diabetes.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Insulin Drugs for Diabetes manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Insulin Drugs for Diabetes by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Insulin Drugs for Diabetes in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Ultra-long-acting Insulin
- Short-acting Insulin
- Rapid-acting Insulin
- Long-acting Insulin
- Intermediate-acting Insulin
Applications
- Hospital and Clinic
- Retail Pharmacies
- Other
Companies covered
- AstraZeneca
- Bayer
- Eli Lilly
- HTBT
- Merck
- Novartis
- Novo Nordisk
- Sanofi
- Tonghua Dongbao Pharmaceutical
- Gan & Lee Pharmaceuticals
- Kamp Pharmaceuticals
- Johnson & Johnson
- Wanbang Biopharmaceuticals
- Takeda
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Insulin Drugs for Diabetes Market Size (2021-2032)
- 2.2.2 Global Insulin Drugs for Diabetes Sales (2021-2032)
- 2.2.3 Global Insulin Drugs for Diabetes Market Average Price (2021-2032)
- 2.3 Insulin Drugs for Diabetes by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Ultra-long-acting Insulin
- 2.3.3 Short-acting Insulin
- 2.3.4 Rapid-acting Insulin
- 2.3.5 Long-acting Insulin
- 2.3.6 Intermediate-acting Insulin
- 2.4 Insulin Drugs for Diabetes by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital and Clinic
- 2.4.3 Retail Pharmacies
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Insulin Drugs for Diabetes Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Insulin Drugs for Diabetes Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Insulin Drugs for Diabetes Revenue of Manufacturers (2021-2026)
- 3.4 Global Insulin Drugs for Diabetes Average Price by Manufacturers (2021-2026)
- 3.5 Global Insulin Drugs for Diabetes Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Insulin Drugs for Diabetes, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Insulin Drugs for Diabetes, Product Type & Application
- 3.8 Global Manufacturers of Insulin Drugs for Diabetes, Established Date
- 3.9 Global Insulin Drugs for Diabetes Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 AstraZeneca
- 4.1.1 AstraZeneca Company Information
- 4.1.2 AstraZeneca Business Overview
- 4.1.3 AstraZeneca Insulin Drugs for Diabetes Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 AstraZeneca Insulin Drugs for Diabetes Product Portfolio
- 4.1.5 AstraZeneca Recent Developments
- 4.2 Bayer
- 4.2.1 Bayer Company Information
- 4.2.2 Bayer Business Overview
- 4.2.3 Bayer Insulin Drugs for Diabetes Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Bayer Insulin Drugs for Diabetes Product Portfolio
- 4.2.5 Bayer Recent Developments
- 4.3 Eli Lilly
- 4.3.1 Eli Lilly Company Information
- 4.3.2 Eli Lilly Business Overview
- 4.3.3 Eli Lilly Insulin Drugs for Diabetes Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Eli Lilly Insulin Drugs for Diabetes Product Portfolio
- 4.3.5 Eli Lilly Recent Developments
- 4.4 HTBT
- 4.4.1 HTBT Company Information
- 4.4.2 HTBT Business Overview
- 4.4.3 HTBT Insulin Drugs for Diabetes Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 HTBT Insulin Drugs for Diabetes Product Portfolio
- 4.4.5 HTBT Recent Developments
- 4.5 Merck
- 4.5.1 Merck Company Information
- 4.5.2 Merck Business Overview
- 4.5.3 Merck Insulin Drugs for Diabetes Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Merck Insulin Drugs for Diabetes Product Portfolio
- 4.5.5 Merck Recent Developments
- 4.6 Novartis
- 4.6.1 Novartis Company Information
- 4.6.2 Novartis Business Overview
- 4.6.3 Novartis Insulin Drugs for Diabetes Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Novartis Insulin Drugs for Diabetes Product Portfolio
- 4.6.5 Novartis Recent Developments
- 4.7 Novo Nordisk
- 4.7.1 Novo Nordisk Company Information
- 4.7.2 Novo Nordisk Business Overview
- 4.7.3 Novo Nordisk Insulin Drugs for Diabetes Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Novo Nordisk Insulin Drugs for Diabetes Product Portfolio
- 4.7.5 Novo Nordisk Recent Developments
- 4.8 Sanofi
- 4.8.1 Sanofi Company Information
- 4.8.2 Sanofi Business Overview
- 4.8.3 Sanofi Insulin Drugs for Diabetes Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Sanofi Insulin Drugs for Diabetes Product Portfolio
- 4.8.5 Sanofi Recent Developments
- 4.9 Tonghua Dongbao Pharmaceutical
- 4.9.1 Tonghua Dongbao Pharmaceutical Company Information
- 4.9.2 Tonghua Dongbao Pharmaceutical Business Overview
- 4.9.3 Tonghua Dongbao Pharmaceutical Insulin Drugs for Diabetes Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Tonghua Dongbao Pharmaceutical Insulin Drugs for Diabetes Product Portfolio
- 4.9.5 Tonghua Dongbao Pharmaceutical Recent Developments
- 4.10 Gan & Lee Pharmaceuticals
- 4.10.1 Gan & Lee Pharmaceuticals Company Information
- 4.10.2 Gan & Lee Pharmaceuticals Business Overview
- 4.10.3 Gan & Lee Pharmaceuticals Insulin Drugs for Diabetes Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Gan & Lee Pharmaceuticals Insulin Drugs for Diabetes Product Portfolio
- 4.10.5 Gan & Lee Pharmaceuticals Recent Developments
- 4.11 Kamp Pharmaceuticals
- 4.11.1 Kamp Pharmaceuticals Company Information
- 4.11.2 Kamp Pharmaceuticals Business Overview
- 4.11.3 Kamp Pharmaceuticals Insulin Drugs for Diabetes Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Kamp Pharmaceuticals Insulin Drugs for Diabetes Product Portfolio
- 4.11.5 Kamp Pharmaceuticals Recent Developments
- 4.12 Johnson & Johnson
- 4.12.1 Johnson & Johnson Company Information
- 4.12.2 Johnson & Johnson Business Overview
- 4.12.3 Johnson & Johnson Insulin Drugs for Diabetes Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Johnson & Johnson Insulin Drugs for Diabetes Product Portfolio
- 4.12.5 Johnson & Johnson Recent Developments
- 4.13 Wanbang Biopharmaceuticals
- 4.13.1 Wanbang Biopharmaceuticals Company Information
- 4.13.2 Wanbang Biopharmaceuticals Business Overview
- 4.13.3 Wanbang Biopharmaceuticals Insulin Drugs for Diabetes Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Wanbang Biopharmaceuticals Insulin Drugs for Diabetes Product Portfolio
- 4.13.5 Wanbang Biopharmaceuticals Recent Developments
- 4.14 Takeda
- 4.14.1 Takeda Company Information
- 4.14.2 Takeda Business Overview
- 4.14.3 Takeda Insulin Drugs for Diabetes Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Takeda Insulin Drugs for Diabetes Product Portfolio
- 4.14.5 Takeda Recent Developments
5 Global Insulin Drugs for Diabetes Market Scenario by Region
- 5.1 Global Insulin Drugs for Diabetes Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Insulin Drugs for Diabetes Sales by Region: 2021-2032
- 5.2.1 Global Insulin Drugs for Diabetes Sales by Region: 2021-2026
- 5.2.2 Global Insulin Drugs for Diabetes Sales by Region: 2027-2032
- 5.3 Global Insulin Drugs for Diabetes Revenue by Region: 2021-2032
- 5.3.1 Global Insulin Drugs for Diabetes Revenue by Region: 2021-2026
- 5.3.2 Global Insulin Drugs for Diabetes Revenue by Region: 2027-2032
- 5.4 North America Insulin Drugs for Diabetes Market Facts & Figures by Country
- 5.4.1 North America Insulin Drugs for Diabetes Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Insulin Drugs for Diabetes Sales by Country (2021-2032)
- 5.4.3 North America Insulin Drugs for Diabetes Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Insulin Drugs for Diabetes Market Facts & Figures by Country
- 5.5.1 Europe Insulin Drugs for Diabetes Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Insulin Drugs for Diabetes Sales by Country (2021-2032)
- 5.5.3 Europe Insulin Drugs for Diabetes Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Insulin Drugs for Diabetes Market Facts & Figures by Country
- 5.6.1 Asia Pacific Insulin Drugs for Diabetes Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Insulin Drugs for Diabetes Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Insulin Drugs for Diabetes Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Insulin Drugs for Diabetes Market Facts & Figures by Country
- 5.7.1 South America Insulin Drugs for Diabetes Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Insulin Drugs for Diabetes Sales by Country (2021-2032)
- 5.7.3 South America Insulin Drugs for Diabetes Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Insulin Drugs for Diabetes Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Insulin Drugs for Diabetes Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Insulin Drugs for Diabetes Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Insulin Drugs for Diabetes Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Insulin Drugs for Diabetes Sales by Type (2021-2032)
- 6.1.1 Global Insulin Drugs for Diabetes Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Insulin Drugs for Diabetes Sales Market Share by Type (2021-2032)
- 6.2 Global Insulin Drugs for Diabetes Revenue by Type (2021-2032)
- 6.2.1 Global Insulin Drugs for Diabetes Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Insulin Drugs for Diabetes Revenue Market Share by Type (2021-2032)
- 6.3 Global Insulin Drugs for Diabetes Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Insulin Drugs for Diabetes Sales by Application (2021-2032)
- 7.1.1 Global Insulin Drugs for Diabetes Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Insulin Drugs for Diabetes Sales Market Share by Application (2021-2032)
- 7.2 Global Insulin Drugs for Diabetes Revenue by Application (2021-2032)
- 7.2.1 Global Insulin Drugs for Diabetes Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Insulin Drugs for Diabetes Revenue Market Share by Application (2021-2032)
- 7.3 Global Insulin Drugs for Diabetes Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Insulin Drugs for Diabetes Value Chain Analysis
- 8.1.1 Insulin Drugs for Diabetes Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Insulin Drugs for Diabetes Production Mode & Process
- 8.2 Insulin Drugs for Diabetes Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Insulin Drugs for Diabetes Distributors
- 8.2.3 Insulin Drugs for Diabetes Customers
9 Global Insulin Drugs for Diabetes Analyzing Market Dynamics
- 9.1 Insulin Drugs for Diabetes Industry Trends
- 9.2 Insulin Drugs for Diabetes Industry Drivers
- 9.3 Insulin Drugs for Diabetes Industry Opportunities and Challenges
- 9.4 Insulin Drugs for Diabetes Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst